About
I was appointed Chief Scientific Officer at Compugen in May 2023. In my role, I’m…
Articles by Eran
-
Compugen is looking for a part time Animal Facility Technician to work on our facilities in Tel-Aviv University
Compugen is looking for a part time Animal Facility Technician to work on our facilities in Tel-Aviv University
By Eran Ophir
Activity
-
Join Our Research Team! Are you an ambitious MSc, PhD, or postdoctoral fellow with a passion for groundbreaking research? We’re seeking talented…
Join Our Research Team! Are you an ambitious MSc, PhD, or postdoctoral fellow with a passion for groundbreaking research? We’re seeking talented…
Liked by Eran Ophir
-
This week, we had the pleasure of hosting Michal Golan Mashiach, Ph.D, CEO of Edity Therapeutics, and Ofer Levy, VP of R&D, at our Hyderabad…
This week, we had the pleasure of hosting Michal Golan Mashiach, Ph.D, CEO of Edity Therapeutics, and Ofer Levy, VP of R&D, at our Hyderabad…
Liked by Eran Ophir
-
A new paper alert: We report that glatiramer acetate (GA, aka Copaxone), an immunomodulatory drug prescribed for patients with multiple sclerosis…
A new paper alert: We report that glatiramer acetate (GA, aka Copaxone), an immunomodulatory drug prescribed for patients with multiple sclerosis…
Liked by Eran Ophir
Experience
Education
-
Weizmann Institute of Science
-
Developed cell therapy for the induction of tolerance to Bone-Marrow Transplantation and eliminating hematological malignancies.
- Received the Haim Holtzman Prize for my PhD -
-
• Graduated Magna Cum Laude in Computer Science
• Graduated Summa Cum Laude in Biology
Publications
-
Therapeutic Targeting of Checkpoint Receptors within the DNAM-1 Axis
Cancer Discovery
-
PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function
Cancer Immunology Research
-
Mouse PVRIG Has CD8+ T Cell–Specific Coinhibitory Functions and Dampens Antitumor Immunity
Cancer immunology research
-
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
Science Transnational Medicine
-
Personalized approaches to active immunotherapy in cancer
BBA reviews on cancer
-
Induction of tolerance in organ recipients by hematopoietic stem cell transplantation
International Immunopharmacology
Patents
-
Anti third party central memory central memory T cells, methods of producing same and use same in transplantation and disease treatment
Issued US20180193384A1
The present invention, relates to non-GVHD inducing anti-third party cells comprising central memory T-lymphocyte phenotype. It relates to their generation and use in transplantation and in disease treatment.
Other inventors -
-
Use of anti third party central memory T cells for anti-leukemia/lymphoma treatment
Issued US 61/380,716
The present invention relates to non-graft versus host disease (GVHD) inducing anti-third party cells comprising a central memory T-lymphocyte phenotype and to their use for graft versus leukemia/lymphoma treatment.
Other inventors -
-
GENETICALLY MODIFIEDANTI-THIRD PARTY CENTRAL MEMORY T CELLS AND USE OF SAME IN IMMUNOTHERAPY
Issued US202/08034A1
An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is disclosed. Methods of generating same and using same are also disclosed.
Other inventors
Honors & Awards
-
The Haim Holtzman Memorial Prize in recognition of Scientific accomplishments
-
-
Katzir Travell Fellowship
-
-
The Weizmann Institute of Science Dean's prize in recognition of academic excellence and scientific accomplishments
-
-
Graduated B.Sc. with honors
-
-
Excellence Memorial Scholarship
-
-
Excellence Memorial Scholarship
-
-
Manny Foundation Excellence Award
-
Recommendations received
1 person has recommended Eran
Join now to viewMore activity by Eran
-
Striving for excellence, trust and leadership, core to our company culture were in play as some of our teams recently gathered for a 2-day in person…
Striving for excellence, trust and leadership, core to our company culture were in play as some of our teams recently gathered for a 2-day in person…
Liked by Eran Ophir
-
We are delighted to welcome our new Chief Financial Officer David S.. Read more about David on the leadership section of our website…
We are delighted to welcome our new Chief Financial Officer David S.. Read more about David on the leadership section of our website…
Liked by Eran Ophir
-
Startup spotlight💡: Israel-based Biomica Ltd. is pushing the boundaries of immuno-oncology with its innovative microbiome-based therapies. →…
Startup spotlight💡: Israel-based Biomica Ltd. is pushing the boundaries of immuno-oncology with its innovative microbiome-based therapies. →…
Liked by Eran Ophir
-
Very proud to be a part of Beilinson - Rabin Medical Center ! #healthcare #medicalcenter #medicine #excellence
Very proud to be a part of Beilinson - Rabin Medical Center ! #healthcare #medicalcenter #medicine #excellence
Liked by Eran Ophir
-
Congratulations to Compugen Ltd.! The company announced that the U.S. Food and Drug Administration has cleared the investigational new drug…
Congratulations to Compugen Ltd.! The company announced that the U.S. Food and Drug Administration has cleared the investigational new drug…
Liked by Eran Ophir
-
Compugen are delighted to share our success in achieving FDA IND clearance for COM503 triggering a $30 million milestone payment from our partner…
Compugen are delighted to share our success in achieving FDA IND clearance for COM503 triggering a $30 million milestone payment from our partner…
Liked by Eran Ophir
-
🚀 We're hiring @Compugen! Join our dynamic finance team as a Junior FP&A Analyst. If you're passionate about financial planning and analysis, and…
🚀 We're hiring @Compugen! Join our dynamic finance team as a Junior FP&A Analyst. If you're passionate about financial planning and analysis, and…
Liked by Eran Ophir
-
I am grateful to Saul Orbach for inviting me to guest lecture at The Hebrew University Business School's introduction to Venture Capital course. It…
I am grateful to Saul Orbach for inviting me to guest lecture at The Hebrew University Business School's introduction to Venture Capital course. It…
Liked by Eran Ophir
-
Compugen’s SVP Preclinical Development and Corporate Operations Pierre Ferre was on stage at the recent 12th Antibody Industrial Symposium 2024 (AIS…
Compugen’s SVP Preclinical Development and Corporate Operations Pierre Ferre was on stage at the recent 12th Antibody Industrial Symposium 2024 (AIS…
Liked by Eran Ophir
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More